评估植入治疗对糖尿病患者的益处,我们比较了(一)健康,(ii)控制良好的T2DM和(iii)控制不佳的T2DM患者,在口腔健康相关的生活质量(OHRQoL)和对修复后12个月的下颌2-种植体覆盖义齿的满意度方面。
这个单中心,prospective,队列研究招募了165名无牙成年人(HbA1c<12%),在前下颌骨接受两个骨内植入物以支持下颌覆盖义齿。参与者被纳入是否患有T2DM,2型糖尿病参与者根据HbA1c分为良好控制组(<8.1%)和不良控制组(≥8.1%)。参与者提供了对OHIP-20(OHRQoL)和McGill义齿满意度问卷的回答,植入治疗前以及使用Locator附件插入覆盖义齿后6个月和12个月。在相同的时间点测量HbA1c。使用广义估计方程(α=0.025)验证了群体和时间的影响。
在12个月时,137名与会者作了答复。在6个月和12个月时,两个糖尿病组的OHRQoL改善程度与非糖尿病对照组相同。患者满意度显示出相似的改善,没有组间差异,并且在6个月和12个月时发现了相似的增加。HbA1c不受时间或群体影响。
牙科种植疗法显著改善了患者对T2DM患者下颌双种植体覆盖义齿的获益,这与健康无牙个体发现的相似。重要的是,这些益处扩展到血糖控制不佳的个体。在插入后的12个月内,添加2个植入物支持的下颌覆盖义齿不会影响血糖状态。
由于更好地理解植入治疗相对于血糖状态的风险,这项研究表明,植入治疗可为T2DM患者的QoL带来重要益处,而与血糖状况无关.
To evaluate the benefits of implant therapy for patients with diabetes, we compared (i) healthy, (ii) well controlled T2DM and (iii) poorly controlled T2DM patients, in terms of oral health-related quality of life (OHRQoL) and satisfaction with mandibular 2-implant overdentures over 12 months following restoration.
This single-center, prospective, cohort study recruited 165 edentulous adults (HbA1c<12%) to receive two endosseous implants in the anterior mandible to support mandibular overdentures. Participants were enrolled as having T2DM or not, with T2DM participants divided according to HbA1c into well-controlled (<8.1%) and poorly controlled (≥ 8.1%) groups. Participants provided responses to the OHIP-20 (OHRQoL) and the McGill Denture Satisfaction Questionnaire, before implant therapy and 6 and 12 months after overdenture insertion using Locator attachments. HbA1c was measured at the same time points. The effect of groups and time was verified using generalized estimating equations (α=0.025).
At 12 months, 137 participants provided responses. The two diabetes groups showed improvements in OHRQoL to the same extent as the non-diabetic control group at both 6 and 12 months. Patient satisfaction showed similar improvements with no between-group differences and similar increases identified at 6 and 12 months. HbA1c was not affected by time or groups.
Dental implant therapy provided significant improvements in patient-perceived benefits of mandibular two-implant overdentures for T2DM individuals, which are similar to those found for healthy edentulous individuals. Importantly, those benefits extend to those individuals with poorly controlled glycaemia. The addition of 2-implant supported mandibular overdentures did not affect glycaemic status over 12 months following insertion.
As risks for implant therapy relative to glycaemic status are better understood, this study documents that implant therapy may offer important benefits in QoL for T2DM patients independent of glycaemic status.